Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

Furst, D E; Keystone, E C; Fleischmann, R; Mease, P; Breedveld, F C; Smolen, J S; Kalden, J R; Braun, J; Bresnihan, B; Burmester, G R; De Benedetti, F; Dörner, T; Emery, P; Gibofsky, A; Kavanaugh, A; Kirkham, B; Schiff, M H; Sieper, J; Singer, N; Van Riel, P L C M; Weinblatt, M E; Weisman, M H; Winthrop, K

Furst, D E; Keystone, E C; Fleischmann, R; Mease, P; Breedveld, F C; Smolen, J S; Kalden, J R; Braun, J; Bresnihan, B; Burmester, G R; De Benedetti, F; Dörner, T; Emery, P; Gibofsky, A; Kavanaugh, A; Kirkham, B; Schiff, M H; Sieper, J; Singer, N; Van Riel, P L C M; Weinblatt, M E; Weisman, M H; Winthrop, K.

Affiliation

Furst DE; University of California at Los Angeles, Los Angeles, USA. defurst@mednet.ucla.edu

Ann Rheum Dis ; 69 Suppl 1: i2-29, 2010 Jan.

Article in En | MEDLINE | ID: mdl-19995740

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rheumatic Diseases / Antirheumatic Agents / Immunosuppressive Agents Type of study: Guideline Limits: Humans Language: En Journal: Ann Rheum Dis Year: 2010 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google